Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024 [1] Group 1: Class Action Details - Investors who purchased Allarity securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 12, 2024 [3] - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of Dovitinib, a drug candidate for renal cell carcinoma [5] - It is claimed that Allarity engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following the announcement of an investigation into its conduct, resulting in materially false public statements [5]
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR